Antiretroviral resistance in HIV: Difference between revisions
From IDWiki
(Created page with "* Genotyping sequences reverse transcriptase, integrase, and protease * Resistance point mutations names as wild-type amino acid, position, and mutant amino acid (e.g. K '''10...") |
mNo edit summary |
||
Line 35: | Line 35: | ||
| Q '''151''' '''M''' |
| Q '''151''' '''M''' |
||
|- |
|- |
||
| rowspan=6 | Thymidine analogue-associated mutations ( |
| rowspan=6 | Thymidine analogue-associated mutations (TAMs) multi-NRTI resistance |
||
| M '''41''' '''L''' |
| M '''41''' '''L''' |
||
|- |
|- |
Revision as of 20:06, 5 July 2020
- Genotyping sequences reverse transcriptase, integrase, and protease
- Resistance point mutations names as wild-type amino acid, position, and mutant amino acid (e.g. K 103 N)
- Bulk sequencing can only detect mutations that represent >20% of HIV
Drug | Mutation |
---|---|
NRTIs | |
69 insertion complex multi-NRTI resistance | M 41 L |
A 62 V | |
* 69 insert | |
K 70 R | |
L 210 W | |
T 215 Y F | |
K 219 Q E | |
151 complex multi-NRTI resistance | A 62 V |
V 75 I | |
F 77 L | |
F 116 Y | |
Q 151 M | |
Thymidine analogue-associated mutations (TAMs) multi-NRTI resistance | M 41 L |
D 67 N | |
K 70 R | |
L 210 W | |
T 215 Y F | |
K 219 Q W | |
Abacavir | K 65 R E N |
L 74 V | |
Y 115 F | |
M 184 V | |
Emtricitabine | K 65 R E N |
M 184 V I | |
Lamivudine | K 65 R E N |
M 184 V I | |
Tenofovir | K 65 R E N |
K 70 E | |
Zidovudine | M 41 L |
D 67 N | |
K 70 R | |
L 210 W | |
T 215 Y F | |
K 219 Q E | |
NNRTIs | |
Doravirine | V 106 A I M T |
Y 188 C L H | |
G 190 E | |
P 225 H | |
F 227 C L R | |
M 230 L | |
L 234 I | |
Efavirenz | L 100 I |
K 101 P | |
K 103 N S | |
V 106 M | |
V 108 I | |
Y 181 C I | |
Y 188 L | |
G 190 S A | |
P 225 H | |
M 230 L | |
Nevirapine | L 100 I |
K 101 P | |
K 103 N S | |
V 106 A M | |
V 108 I | |
Y 181 C I | |
Y 188 C L H | |
G 190 A | |
M 230 L | |
Rilpivirine | L 100 I |
K 101 E P | |
E 138 A G K Q R | |
V 179 L | |
Y 181 C I V | |
Y 188 L | |
H 221 Y | |
F 227 C | |
M 230 I L | |
Protease inhibitors | |
Atazanavir | L 10 I F V C |
G 16 E | |
K 20 R M I T V | |
L 24 I | |
V 32 I | |
L 33 I F V | |
E 34 Q | |
M 36 I L V | |
M 46 I L | |
G 48 V | |
I 50 L | |
F 53 L Y | |
I 54 L V M T A | |
D 60 E | |
I 62 V | |
I 64 L M V | |
A 71 V I T L | |
G 73 C S T A | |
V 82 A T F I | |
I 84 V | |
I 85 V | |
N 88 S | |
L 90 M | |
I 93 L M | |
Darunavir | V 11 I |
V 32 I | |
L 33 F | |
I 47 V | |
I 50 V | |
I 54 M L | |
T 74 P | |
L 76 V | |
I 84 V | |
L 89 V | |
I N S T Is | |
Bictegravir | G 118 R |
E 138 K | |
G 140 S | |
Q 148 H | |
R 263 K | |
Cabotegravir | T 66 K |
G 118 R | |
E 138 A K T | |
G 140 A C R S | |
Q 148 H K R | |
S 153 F Y | |
N 155 H | |
R 263 K | |
Dolutegravir | G 118 R |
F 121 Y | |
E 138 A K T | |
G 140 A S | |
Q 148 H K R | |
N 155 H | |
R 263 K | |
Elvitegravir | T 66 I A K |
E 92 Q G | |
T 97 A | |
F 121 Y | |
S 147 G | |
Q 148 H K R | |
N 155 H | |
R 263 K | |
Raltegravir | L 74 M |
E 92 Q | |
T 97 A | |
F 121 Y | |
E 138 A K | |
G 140 A S | |
Y 143 R H C | |
Q 148 H K R | |
N 155 H | |
R 263 K |